S&P 500   3,335.86 (-0.47%)
DOW   27,411.04 (-0.63%)
QQQ   276.55 (-0.23%)
AAPL   114.09 (-0.76%)
MSFT   208.00 (-0.69%)
FB   259.49 (+1.04%)
GOOGL   1,459.63 (+0.07%)
AMZN   3,162.68 (-0.36%)
TSLA   425.72 (+1.07%)
NVDA   529.33 (+1.52%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.73 (+2.03%)
GE   6.08 (-1.94%)
AMD   82.00 (+3.17%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.06 (-1.26%)
NFLX   490.98 (+0.07%)
DIS   124.14 (-1.47%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
S&P 500   3,335.86 (-0.47%)
DOW   27,411.04 (-0.63%)
QQQ   276.55 (-0.23%)
AAPL   114.09 (-0.76%)
MSFT   208.00 (-0.69%)
FB   259.49 (+1.04%)
GOOGL   1,459.63 (+0.07%)
AMZN   3,162.68 (-0.36%)
TSLA   425.72 (+1.07%)
NVDA   529.33 (+1.52%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.73 (+2.03%)
GE   6.08 (-1.94%)
AMD   82.00 (+3.17%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.06 (-1.26%)
NFLX   490.98 (+0.07%)
DIS   124.14 (-1.47%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
S&P 500   3,335.86 (-0.47%)
DOW   27,411.04 (-0.63%)
QQQ   276.55 (-0.23%)
AAPL   114.09 (-0.76%)
MSFT   208.00 (-0.69%)
FB   259.49 (+1.04%)
GOOGL   1,459.63 (+0.07%)
AMZN   3,162.68 (-0.36%)
TSLA   425.72 (+1.07%)
NVDA   529.33 (+1.52%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.73 (+2.03%)
GE   6.08 (-1.94%)
AMD   82.00 (+3.17%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.06 (-1.26%)
NFLX   490.98 (+0.07%)
DIS   124.14 (-1.47%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
S&P 500   3,335.86 (-0.47%)
DOW   27,411.04 (-0.63%)
QQQ   276.55 (-0.23%)
AAPL   114.09 (-0.76%)
MSFT   208.00 (-0.69%)
FB   259.49 (+1.04%)
GOOGL   1,459.63 (+0.07%)
AMZN   3,162.68 (-0.36%)
TSLA   425.72 (+1.07%)
NVDA   529.33 (+1.52%)
BABA   277.46 (+0.53%)
CGC   14.67 (+3.24%)
MU   50.73 (+2.03%)
GE   6.08 (-1.94%)
AMD   82.00 (+3.17%)
T   28.23 (-0.53%)
F   6.59 (-1.49%)
ACB   4.87 (+1.88%)
GILD   62.06 (-1.26%)
NFLX   490.98 (+0.07%)
DIS   124.14 (-1.47%)
BA   163.69 (-1.44%)
BAC   23.67 (-1.74%)
Log in
NASDAQ:INCY

Incyte Stock Forecast, Price & News

$88.11
-2.25 (-2.49 %)
(As of 09/29/2020 12:34 PM ET)
Add
Compare
Today's Range
$87.42
Now: $88.11▼
$90.42
50-Day Range
$85.07
MA: $91.71▼
$97.56
52-Week Range
$62.48
Now: $88.11▼
$110.36
Volume12,067 shs
Average Volume1.64 million shs
Market Capitalization$19.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Read More
Incyte logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.60 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
Previous Symbol
CUSIP45337C10
CIK879169
Webwww.incyte.com
Phone302-498-6700

Debt

Debt-to-Equity Ratio0.01
Current Ratio3.73
Quick Ratio3.70

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.16 billion
Price / Sales8.93
Cash Flow$2.37 per share
Price / Cash Flow37.23
Book Value$12.06 per share
Price / Book7.31

Profitability

EPS (Most Recent Fiscal Year)$2.23
Net Income$446.91 million
Net Margins-8.00%
Return on Equity-8.06%
Return on Assets-5.94%

Miscellaneous

Employees1,456
Outstanding Shares218,699,000
Market Cap$19.27 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$88.11
-2.25 (-2.49 %)
(As of 09/29/2020 12:34 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Incyte (NASDAQ:INCY) Frequently Asked Questions

How has Incyte's stock price been impacted by Coronavirus (COVID-19)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INCY stock has increased by 22.1% and is now trading at $87.80.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Incyte?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Incyte.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Incyte.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) issued its quarterly earnings results on Tuesday, August, 4th. The biopharmaceutical company reported $1.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.36. The biopharmaceutical company had revenue of $688 million for the quarter, compared to analyst estimates of $617.55 million. Incyte had a negative return on equity of 8.06% and a negative net margin of 8.00%. The company's quarterly revenue was up 29.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.75 EPS.
View Incyte's earnings history.

What price target have analysts set for INCY?

23 brokers have issued twelve-month price targets for Incyte's shares. Their forecasts range from $83.00 to $124.00. On average, they anticipate Incyte's share price to reach $102.37 in the next twelve months. This suggests a possible upside of 16.6% from the stock's current price.
View analysts' price targets for Incyte.

Are investors shorting Incyte?

Incyte saw a increase in short interest in August. As of August 14th, there was short interest totaling 5,440,000 shares, an increase of 11.9% from the July 30th total of 4,860,000 shares. Based on an average trading volume of 1,420,000 shares, the short-interest ratio is currently 3.8 days.
View Incyte's Short Interest.

Who are some of Incyte's key competitors?

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Exelixis (EXEL).
View all competitors.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Kite Pharma (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Who are Incyte's key executives?

Incyte's management team includes the following people:
  • Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $87.80.

How big of a company is Incyte?

Incyte has a market capitalization of $19.20 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.